In vitro activity of amphotericin B cochleates against Leishmania chagasi
Open Access
- 1 March 2011
- journal article
- Published by FapUNIFESP (SciELO) in Memórias do Instituto Oswaldo Cruz
- Vol. 106 (2) , 251-253
Abstract
Cochleate delivery vehicles are a novel lipid-based system with potential for delivery of amphotericin B (AmB). In this study, the efficacy of cochleates was evaluated by examining the in vitro activity of AmB cochleates (CAMB) against Leishmania chagasi in a macrophage model of infection. We demonstrate that CAMB is nontoxic to macrophages at concentrations as high as 2.5 μg/mL, whereas the conventional formulation, AmB deoxycholate, showed high toxicity at this concentration. The in vitro activity of CAMB against L. chagasi was found to be similar to that of the reference drug AmB deoxycholate, with ED50s of 0.017 μg/mL and 0.021 μg/mL, respectively. Considering that L. chagasi affects organs amenable to cochleate-mediated delivery of AmB, we hypothesize that CAMB will be an effective lipid system for the treatment of visceral leishmaniasis.Keywords
This publication has 11 references indexed in Scilit:
- OAK-based cochleates as a novel approach to overcome multidrug resistance in bacteriaThe FASEB Journal, 2010
- Cochleates bridged by drug moleculesInternational Journal of Pharmaceutics, 2008
- Efficacy of Orally Delivered Cochleates Containing Amphotericin B in a Murine Model of AspergillosisAntimicrobial Agents and Chemotherapy, 2002
- Efficacy of Oral Cochleate-Amphotericin B in a Mouse Model of Systemic CandidiasisAntimicrobial Agents and Chemotherapy, 2000
- Antifungal Activity of Amphotericin B Cochleates against Candida albicans Infection in a Mouse ModelAntimicrobial Agents and Chemotherapy, 2000
- A comparative review of conventional and lipid formulations of amphotericin BJournal of Clinical Pharmacy and Therapeutics, 1999
- Amphotericin B Lipid Complex for Invasive Fungal Infections: Analysis of Safety and Efficacy in 556 CasesClinical Infectious Diseases, 1998
- Short-Course, Low-Dose Amphotericin B Lipid Complex Therapy for Visceral Leishmaniasis Unresponsive to AntimonyAnnals of Internal Medicine, 1997
- Short-Course Treatment of Visceral Leishmaniasis with Liposomal Amphotericin B (AmBisome)Clinical Infectious Diseases, 1996
- Lipid Formulations of Amphotericin B: Recent Progress and Future DirectionsClinical Infectious Diseases, 1996